Evofem Biosciences Inc. Common Stock
(NASDAQ:EVFM)
Description
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.
EVFM Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$0.8320 |
Previous Close Volume |
7420000 |
Latest News
- Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 14 Nov 2024 16:38:16
- Evofem Secures Investor Support for Proposed Merger through Voting Agreements 06 Nov 2024 08:02:10
- Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem 28 Oct 2024 08:47:14
- Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025 20 Sep 2024 08:32:10
- Evofem Biosciences Addresses the Impact of GLP-1 Medications on Oral Contraceptive Absorption and Introduces Phexxi as a Non-Oral Solution 20 Aug 2024 08:38:45
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024 14 Aug 2024 07:23:46
- Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st 25 Jul 2024 12:23:34
- Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 23 Jul 2024 09:08:32
- Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter 11 Jun 2024 08:38:44
- Evofem Biosciences Announces Financial Results for the First Quarter of 2024 15 May 2024 06:53:50
- Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO 18 Apr 2024 08:39:05
- Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 27 Mar 2024 08:39:12
- Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal 20 Mar 2024 08:54:09
- For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy 07 Mar 2024 08:08:58
- Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 01 Feb 2024 08:08:58